JAB-21822 + cetuximab

**JAB-21822 + cetuximab** is a combination drug therapy being investigated for the treatment of advanced solid tumors, primarily colorectal cancer with KRAS G12C mutation. JAB-21822 (glecirasib) is a highly selective, covalent oral small molecule inhibitor that targets and irreversibly binds the KRAS G12C mutation, trapping it in its inactive, GDP-bound state and blocking downstream oncogenic signaling pathways involved in tumor growth and survival. Cetuximab is a chimeric monoclonal antibody directed against the Epidermal Growth Factor Receptor (EGFR), inhibiting ligand-induced activation and downstream signaling. This combination is being studied because KRAS G12C inhibitors paired with anti-EGFR monoclonal antibodies have shown increased anti-tumor activity in KRAS G12C mutated colorectal cancer compared to monotherapy[5][2][4]. Key developer is Jacobio Pharma, which is actively conducting clinical trials for JAB-21822 as monotherapy and in combination (including with cetuximab) for multiple advanced solid tumors, notably colorectal cancer[1][4][5][8]. The current development status is Phase II/III for colorectal cancer[5][2].

Brand names

glecirasib

Other names

JAB-21822 + cetuximab